Clinical Trial Update: A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1 [Phase 2]

View source ↗

Summary

Phase 2 trial investigating obinutuzumab induction in relapsed/refractory Waldenström macroglobulinemia (OBI-1).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Polish Myeloma Consortium | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: UNKNOWN